Mallinck­rodt bags an­oth­er mi­cro­cap biotech, pick­ing up Ocera’s failed drug in $117M buy­out

Back at the be­gin­ning of the year, Ocera looked like just about any oth­er small de­vel­op­er af­ter a head-on col­li­sion with bad da­ta. Its Phase …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.